Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.

Louise LaisneBenedicte NevenJean-Hugues DalleClaire GalambrunMaxime EsvanCecile RenardFanny RiallandAnne SirventVirginie Gandemernull null

Published in: Pediatric blood & cancer (2020)

Ruxolitinib may constitute a promising second-line treatment for children with steroid-refractory aGVHD that should be validated in a prospective large-scale pharmacokinetic and efficacy trial.

Keyphrases

young adults
liver failure
clinical trial
study protocol
randomized controlled trial
respiratory failure
drug induced
intensive care unit
combination therapy
acute respiratory distress syndrome
extracorporeal membrane oxygenation
replacement therapy